Enzymatic synthesis of heparin related polysaccharides on sensor chips: Rapid screening of heparin–protein interactions by Muñoz, Eva et al.
Enzymatic synthesis of heparin related polysaccharides on
sensor chips: Rapid screening of heparin–protein interactions
Eva Muñoza,b,c, Ding Xud, Fikri Avcia,b,c, Melissa Kempa,b,c, Jian Liud, and Robert J.
Linhardta,b,c,*
aDepartment of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY
12180, USA
bDepartment of Biology, Rensselaer Polytechnic Institute, Troy, NY 12180, USA
cDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY
12180, USA
dDepartment of Medicinal Chemistry, University of North Carolina, Chapel Hill, NC 27599, USA
Abstract
The biological roles of heparin (HP) and heparan sulfate (HS) are mediated mainly through their
interaction with proteins. In the present work, we provide a rapid method for screening HP/HS–
protein interactions providing structural data on the key sulfo groups that participate in the
binding. A library of polysaccharides structurally related to HP was prepared by immobilizing the
biotinylated N-sulfated K5 polysaccharide (N-sulfoheparosan) on sensor chips followed by
selective modification of this polysaccharide with enzymes that participate in HP/HS biosynthesis.
The polysaccharides synthesized on the surface of the sensor chips differ in the number and
position of sulfo groups present both on uronic acid and glucosamine residues. Surface plasmon
resonance was used to measure the interaction of each member of this polysaccharide library with
antithrombin III (ATIII), to afford structural information on sulfo groups required for this HP/HS–
protein interaction. This method is viewed as widely applicable for the study of the structure–
activity relationship (SAR) of HP/HS–protein interactions.
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Heparin (HP) and heparan sulfate (HS) are structurally related glycosaminoglycans (GAGs)
that participate in numerous important biological processes such as blood coagulation, viral
and bacterial entry and infection, angiogenesis, and cancer development [1–6]. They are
linear polysaccharides with a repeating disaccharide unit of 1,4-linked uronic acid (D-
glucuronic or L-iduronic acid) and D-glucosamine residues. Both uronic acid and
glucosamine can contain sulfo groups at different positions of the pyranose ring including 2-
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O-sulfo substitution of the uronic acid residue, and 2-N-, 3-O-, and 6-O-sulfo substitution in
the glucosamine residue. All these structural variations make HP/HS a very heterogeneous
highly charged polysaccharide [7]. HP/HS carry out their biological functions primarily by
their interaction with proteins in which the sulfo groups of the GAG electrostatically interact
or hydrogen bond with basic amino acids of the target protein [8]. Frequently, heparin-
binding proteins interact with HP/HS specifically and with high affinity, as dictated by the
number and relative position of the sulfo groups in the interacting oligosaccharide sequence
[9,10]. The most widely studied example is the highly specific binding of HP/HS with the
serine protease inhibitor, ATIII. The effective interaction between ATIII and HP/HS
requires the presence of a sulfo group in position 3 of the central glucosamine of a
pentasaccharide of sequence GlcNS6S-GlcA-GlcNS3S ± 6S-IdoA2S-GlcNS6S [11,12]. In
addition to ATIII, there are a large and increasing number of HP/HS-binding proteins
involved in important biological processes [8]. Structural information has been reported in
some of the HP/HS–protein complexes revealing the relative importance of certain sulfo
groups in specific positions of the uronic acid and/or glucosamine residues [10,13].
Unfortunately, in most cases there is a lack of general approaches for identifying key sulfo
groups for protein-binding specificities.
Here we present a method for a rapid screening of HP/HS–protein interactions. A small
library of polysaccharides structurally related to HP/HS was synthesized on a sensor chip
using bacterially expressed C5-epimerase and sulfotransferases, and the ability of each
polysaccharide to bind ATIII was analyzed using surface plasmon resonance (SPR). This
method measures the interaction between an immobilized ligand on a sensor chip and an
analyte that is passed over the surface of the sensor chip. The mass of analyte that binds to
the immobilized ligand is monitored as a function of time (sensorgram). Thus, binding is
determined in real time and detailed analysis of the resulting sensorgrams provides
quantitative kinetic and binding-affinity data [14]. In the present work, heparosan, bacterial
capsular polysaccharide from Escherichia coli K5 strain, was chemically modified through
de-N-acetylation and N-sulfonation to afford N-sulfoheparosan. After immobilization of N-
sulfoheparosan, it was enzymatically modified with C5-epimerase and various O-
sulfotransferases involved in HP/HS biosynthesis. Selective O-sulfonation of N-
sulfoheparosan afforded sensor chips containing a variety of polysaccharides structurally
related to HP/HS. These polysaccharides are missing sulfo groups at defined positions in
their uronic acid and/or glucosamine residues. The screening of this library relied on the
well-studied HP–ATIII interaction to validate the utility of this approach for understanding
the SAR of HP/HS–protein interactions.
Materials and methods
Materials
Heparosan was purified from E. coli K5 strain (from American Type Culture Collection) as
described in a previous report [15]. Porcine intestinal heparin (sodium salt) was from Sigma
(St. Louis, MO). DEAE Sephadex ion exchange resin (50 g) and S200 HR Sephacryl GPC
resin (250 ml) were from Sigma (St. Louis, MO). Sulfo-N-hydroxy-succinimide-long chain-
biotin (sulfo-NHS-LC-biotin) was from Pierce (Rockford, IL). Streptavidin (SA) sensor
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chips and HBS–EP buffer (0.01M Hepes, pH 7.4, 0.15M NaCl, 3 mM EDTA, and 0.005%
surfactant P20) were from BIAcore (Biacore AB, Uppsala, Sweden). Double distilled water
and HPLC grade water were used. All buffers were filtered (0.22 μm) and degassed prior to
using. SPR measurements were performed on a BIAcore 3000 instrument with BIAcore
3000 control and BIA evaluation software (ver. 4.0.1).
Expression and purification of HS biosynthesis enzymes
The catalytic domain of human C5-epimerase (E53-N609) was cloned into pMAL-c2X
vector (New England Biolabs) using the BamH1 and HindIII sites to generate a maltose-
binding protein (MBP)-epimerase fusion protein. The full length cDNA of C5-epimerase
was a gift from Dr. Rosenberg (Massachusetts Institute of Technology). Expression of C5-
epimerase was achieved in Origami-B cells (Novagen) carrying pGro7 plasmid (Takara,
Japan) which expresses chaperonin proteins GroEL and GroES. The bacteria were grown in
LB medium supplemented with 2 mg/ml glucose, 12.5 μg/ml tetracycline, 15 μg/ml
kanamycin, 35 μg/ml chloramphenicol, and 50 μg/ml carbenicillin at 37 °C. When the OD
600 nm reached 0.6–0.8, IPTG and L-arabinose were added to a final concentration of 0.1
mM and 1 mg/ml, respectively. The protein was purified following the protocol provided by
the manufacturer. The purified proteins migrated at 100 kDa on SDS–PAGE with the purity
greater than 60%.
The expression and purification of mouse 6-OST-1 and Chinese hamster 2-OST were
described in our previous publication [16]. The expression and purification of mouse 3-
OST-1 were described elsewhere [17].
Determination of the activities of HS biosynthetic enzymes
The activity of C5-epimerase was determined by coupling the reactions of epimerization and
2-O-sulfation using N-sulfoheparosan as a substrate. Briefly, purified MBP-epimerase (~6
μg) was incubated with N-sulfoheparosan (5 μg) in 100 μl of a buffer containing 50 mM
Mes, 10 mM MnCl2, 5 mM MgCl2, and 1% Triton X-100 (pH 7) at 37 °C for 2 h. MBP-2-
OST (4 μg) was then added into the reaction mixture along with [35S]PAPS (1 × 106 cpm).
The mixture was incubated at 37 °C for another 1 h, and the mixture was subjected to a 200
μl DEAE–Sepharose column to purify [35S]HS. The [35S]HS was degraded to disaccharides
by nitrous acid (pH 1.5). The identities (either GlcA2S-AnMan or IdoA2S-AnMan) of the
resultant 35S-labeled disaccharides were determined by coeluting with appropriate 3H-
labeled disaccharides on reverse-phase ion-pairing HPLC [18]. After the treatment of N-
sulfoheparosan by epimerase followed by 2-OST, greater than 80% of the 35S-labeled
disaccharide mixture was IdoA2S-AnMan, whereas, less than 5% of the 35S-labeled
disaccharides was IdoA2S-AnMan in 2-OST-treated N-sulfoheparosan. The results suggest
that the expressed protein carries the anticipated C5-epimerase activity.
The activities of 2-OST and 6-OST-1 were determined following the published procedures
using completely desulfated N-sulfonated heparin as a substrate [19,20]. The activity of 3-
OST-1 was determined following the procedure described elsewhere [21].
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Preparation and purification of heparosan
Heparosan was prepared from E. coli K5 strain as explained previously [15]. In addition to
following the published procedure, the isolated polysaccharide (20 mg) was further purified
by S200-HR size exclusion column (4.8 × 75 cm) eluted with 200 mM sodium chloride at a
flow rate of 1 ml/min. The fractions containing heparosan were detected by carbazole assay
[22] and then these fractions were dialyzed against distilled water (MWCO 1000 Da) and
lyophilized to obtain the purified product (7.5 mg) for further modifications.
Preparation of N-deacetylated heparosan
Heparosan (7.0 mg) was dissolved in sodium hydroxide (2.0 ml, 2 N), incubated for 24 h at
60 °C, and cooled to room temperature, and was adjusted to pH 7 with concentrated
hydrochloric acid. The reaction product was dialyzed against distilled water (MWCO 1000
Da) and lyophilized to obtain completely N-deacetylated heparosan intermediate (5.0 mg).
Partial biotinylation of N-deacetylated heparosan and heparin
The free amino groups of the unsubstituted glucosamine residues in heparin [23] were
biotinylated following a procedure previously described by our group [24]. N-Deacetylated
heparosan (4.0 mg, in 2 ml of 50 mM sodium bicarbonate) was treated with sulfo-NHS-LC-
biotin (1.6 mg, in 20 μL dimethylformamide ~4 equiv. biotin/polysaccharide chain) to react
with the free amino groups of glucosamine residues of the polysaccharide, following the
general procedure for heparin biotinylation. The reaction product was dialyzed (MWCO
1000 Da) and lyophilized to obtain pure partially biotinylated, N-deacetylated heparosan
(4.0 mg).
N-Sulfonation of biotinylated N-deacetylated heparosan
The partially biotinylated N-deacetylated heparosan intermediate (4.0 mg in 1 ml distilled
water) was treated with sodium bicarbonate (10 mg) and trimethylamine–sulfurtrioxide
complex (10 mg) in a single step and incubated at 50 °C for 12 h. Equal portion of sodium
bicarbonate and trimethylamine–sulfur trioxide was added two more times at 12 h intervals.
The solution was then brought to room temperature and dialyzed overnight against distilled
water (MWCO 1000 Da). The dialyzate was lyophilized to obtain pure, completely N-
substituted, N-sulfoheparosan with less than 4 biotin tags per polysaccharide chain.
Immobilization of biotinylated, N-sulfoheparosan to the SA sensor chips
The SA sensor chip was pre-treated with three consecutive injections (5 μl) of 50 mM NaOH
in 1M NaCl at 5 μl/min, to remove any non-specifically bound contaminants. Biotinylated,
N-sulfoheparosan (0.1 mg/ml in HBS–EP running buffer) was flowed at 37 °C (5 μl/min,
manual injection) over one or two flow cells simultaneously followed by a 5μl injection of
2M NaCl. The binding of biotinylated, N-sulfoheparosan and heparin–biotin was confirmed
by the observation of a 570–813 RU response.
Enzymatic modification of N-sulfoheparosan on sensor chip surfaces
Each enzyme was diluted in buffer containing 50 mM Mes, 0.1% Triton X-100, 5 mM
MgCl2, 10 mM MnCl2, and 0.1 mg/ml bovine serum albumin. C5-epimerase was diluted to a
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final concentration of 0.5 μM; 2-O-, 6-O-, and 3-O-sulfotransferases were combined with
PAPS (0.08 mM) prior to injection and diluted to a final concentration of 0.6 μM. Every
modification occurred by injecting 15 μl of the enzymatic solution three times for epimerase,
and four times for the sulfotransferases, consecutively at a flow rate of 1 μl/min and
temperature of 37 °C. After every injection, the sensor chip was cleaned with 5 μl of 2 M
NaCl.
Binding studies of the interaction between ATIII and modified N-sulfoheparosan
polysaccharides
ATIII (500 nM in HBS–EP running buffer) was injected at a flow rate of 5 μl/min over the
four flow cells of every sensor chip at 25 °C. The protein was injected for 3 min following
surface regeneration by injection of 5 μl of 2M NaCl, followed by 5 μl NaOH (50 mM)
containing 1M NaCl. The response was monitored as a function of time (sensorgram).
Affinity and kinetic study of the interaction of ATIII with fully (C5-epi,2,6,3-OST) modified N-
sulfoheparosan and HP
Different concentrations of ATIII (10, 25, 50, 75, and 100 nM in HBS–EP running buffer)
were injected at a flow rate of 30 μl/min over a chip with fully modified N-sulfoheparosan or
HP immobilized to one of the flow cells at 25 °C. A kinetic injection mode was used,
leading the protein to flow for 3 min and to be dissociated for the next 3 min. The surface
was regenerated by injection of 30 μl of 2M NaCl, followed by 30 μl NaOH (50 mM)
containing 1 M NaCl. The response was monitored as a function of time (sensorgram).
Results
Enzymatic modification of N-sulfoheparosan polysaccharide on sensor chip surfaces
In the biosynthesis of HP/HS, a copolymer of 1,4-linked GlcA and N-acetylated
glucosamine (GlcNAc) is modified by several enzymes including N-deacetylase/N-
sulfotransferase, C5-epimerase, and 2-O-, 6-O-, and 3-O-sulfotransferases (ST) [25,26]. The
starting polysaccharide (heparosan) used in the present study is structurally related to
HP/HS. Heparosan, a copolymer of 1,4-linked GlcA and GlcNAc, was obtained as a
capsular K5 polysaccharide from E. coli, and chemically N-deacetylated, and N-sulfonated
to afford N-sulfoheparosan. Biotinylated, N-sulfoheparosan was immobilized in three
streptavidin (SA) sensor chips through a strong, non-covalent, biotin–streptavidin
interaction. Four different enzymes were next used to generate a small polysaccharide
library. C5-epimerase converts glucuronic into iduronic acid and sulfotransferases 2-OST, 6-
OST-1, and 3-OST-1 transfer sulfo groups from PAPS to the positions 2-O- of uronic acid,
and 6-O- and 3-O- of the glucosamine. Each modification of the N-sulfoheparosan on the
sensor surface was carried out by injecting the enzyme for 15 min at least three times (in the
presence of PAPS for the O-ST enzymes) under experimental conditions designed to
maximize the efficiency of the enzymatic reaction. Consecutive injections of C5-epimerase,
2-OST, 6-OST-1, and/or 3-OST-1 in each flow cell mimicked the biosynthetic pathway in
which heparosan is converted to HP/HS in the Golgi [26,27]. From our previous solution-
phase studies on these enzymes, we estimate the percent conversion at each step was ~10%
GlcA to IdoA, ~80% IdoA to IdoA2S, ~30% GlcNS to GlcNS6S, and ~10% GlcNS ± 6S to
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GlcNS ± 6S3S [16]. In one flow cell on the sensor chip N-sulfoheparosan was fully
modified, affording a heparin-like polysaccharide. This fully modified polysaccharide, as
well as intermediate polysaccharides, N-sulfoheparosan (control), N-sulfoheparosan
modified with C5-epi, N-sulfoheparosan modified with C5-epi and 2-OST, N-sulfoheparosan
modified with C5-epi, 2-OST and 6-OST, N-sulfoheparosan modified with C5-epi, 2-OST,
and 3-OST, and N-sulfoheparosan modified with C5-epi and 6-OST, lacking sulfo groups at
specific positions of the polysaccharide chain were prepared as a small polysaccharide
library for evaluation by SPR (Fig. 1).
Binding of ATIII to the N-sulfoheparosan derived polysaccharide library
Interaction between ATIII and HP/HS has been studied in great detail [28]. ATIII binds
specifically to the HP pentasaccharide GlcNS6S-GlcA-GlcNS3S ± 6S-IdoA2S-GlcNS6S.
The sulfo group in position 3 of the central glucosamine residue (bolded) is required for the
binding. Sulfo groups in positions 2-O- of uronic acid and N-positions of the glucosamine
residue are known to play a less critical role in binding to ATIII while 6-O-sulfonation of
glucosamine residue appears to be essential [29–32]. These structural characteristics make
the ATIII-HP/HS interaction a good model for the evaluation of our small polysaccharide
library. A solution of ATIII (500 nM in HBS–EP buffer) was injected for 3 min over the
three sensor chips at a flow rate of 5 μl/min. The ability of the modified N-sulfoheparosan
polysaccharides to bind ATIII was observed, monitoring the response as a function of time
(sensorgram). No detectable binding was observed between ATIII and N-sulfoheparosan or
N-sulfoheparosan modified with C5-epi and 6-OST and a weak response was monitored
when ATIII was injected over N-sulfoheparosan modified with C5-epi, N-sulfoheparosan
modified with C5-epi and 2-OST, N-sulfoheparosan modified with C5-epi, 2-OST, and 6-
OST, and N-sulfoheparosan modified with C5-epi, 2-OST, and 3-OST. A much higher
response was obtained when ATIII was flowed over the flow cell containing N-
sulfoheparosan modified with C5-epi, 2-OST, 6-OST, and 3-OST, resulting in a fully
modified, heparin-like polysaccharide (Fig. 2).
Affinity and kinetic study of the interaction of ATIII with N-sulfoheparosan modified with
C5-epi, 2-OST, 6-OST, and 3-OST (heparin-like polysaccharide)
N-Sulfoheparosan modified with C5-epi, 2-OST, 6-OST and 3-OST corresponds to a fully
modified, heparin-like polysaccharide. Thus, its interaction with ATIII should present
binding and kinetic behavior comparable to the HP/HS–ATIII interaction. Different
concentrations of ATIII (10, 25, 50, 75, and 100 nM in HBS–EP) were injected over the
sensor chip containing the heparin-like polysaccharide for 3 min and the dissociation was
monitored for another 3 min. The sensorgrams were globally fitted to a conformational
change model (Fig. 3A) and a dissociation constant of 61.7 nM was calculated (Table 1).
This value is in the same range as the value previously published of the interaction between
ATIII and HP (KD = 50 nM) [12,33,34] or HS (KD = 118 nM) [24]. Additionally we
monitored the interaction of ATIII with HP under the same experimental conditions using
SPR technology obtaining comparable affinity and kinetic data as the ATIII interaction with
N-sulfoheparosan modified with C5-epi, 2-OST, 6-OST, and 3-OST (Table 1).
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HP and HS carry out their biological functions primarily by their interaction with proteins
[8]. The affinity and specificity of the binding depends on the sulfation pattern of the
oligosaccharide sequence [9,10]. Consequently, to establish the SAR of HP/HS protein
interaction, it is important to obtain structural information of the sulfo groups that are
relevant for the protein binding. In the present study, we provide a rapid method for
screening HP/HS–protein interactions to get structural data of key sulfo groups that
participate in the binding event. A library of polysaccharides structurally related to HP was
prepared by immobilizing biotinylated N-sulfoheparosan to sensor chips and subsequent
selective modification with enzymes that participate in the biosynthesis of HP/HS. The
solution-phase, enzymatic synthesis of a heparin-like polysaccharide starting from both
completely de-sulfated heparin and heparosan has been reported [16,35] and the enzymatic
modification of HS by 3-OST-1 on a sensor chip surface has been previously described by
our group [24]. These previous successes suggested it might be possible to synthesize a
small polysaccharide library on sensor chip surface. SPR experiments of the interaction of
ATIII with this small polysaccharide library showed that ATIII bound with high affinity
only to the heparin-like polysaccharide, N-sulfoheparosan modified with C5-epi, 2-OST, 6-
OST, and 3-OST (Fig. 2). The absence of the sulfo group in position 3 of the glucosamine
residues, N-sulfoheparosan modified with C5-epi, 2-OST, and 6-OST, decreased the SPR
response by 10-fold, confirming the essential nature of this sulfo group for ATIII binding.
When 3-O-sulfo groups are present but 6-O-sulfo groups are absent, N-sulfoheparosan
modified with C5-epi, 2-OST, and 3-OST, a reduced sensor response was also observed.
Thus, confirming that the 6-O-sulfo group in the glucosamine residue also makes a
significant contribution to ATIII binding, in agreement with published data [29].
Furthermore, only the sensorgrams obtained for the interaction of ATIII and the heparin-like
polysaccharide, N-sulfoheparosan modified with C5-epi, 2-OST, 6-OST, and 3-OST,
resembled the sensorgrams obtained for HP/HS with ATIII (Fig. 3B). The affinity and
kinetic data of the interaction of ATIII with N-sulfoheparosan modified with C5-epi, 2-OST,
6-OST, and 3-OST and HP were obtained by global fitting of the resulting sensorgrams and
corresponded to a conformational change model. The excellent fit obtained is in agreement
with its well-known conformational change in ATIII that occurs on ATIII binding to HP
[12]. For a given ATIII concentration, the intensity of the sensorgrams obtained for heparin-
like polysaccharide, N-sulfoheparosan modified with C5-epi, 2-OST, 6-OST, and 3-OST,
was lower than that observed for ATIII–HP binding (Fig. 3B), nevertheless, comparable
affinity and kinetic data were obtained (Table 1). These results clearly demonstrate that
modification of N-sulfoheparosan with C5-epimerase, and 2-O-, 6-O-, and 3-OST-1 afforded
a functional ATIII-binding site. Thus, all the enzymatic modifications must have taken
place, supporting the formation of the correct structures for all the polysaccharide
intermediates comprising this small library.
In conclusion, we have developed a method for the chip-based synthesis of a polysaccharide
library as well as a rapid screening method for HP/HS–protein interactions. This method can
be used to identify critical sulfo groups involved in binding. This method has been validated
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using with the well-studied ATIII–HP/HS interaction. Future studies will utilize this smaller
chip-based library to screen other less studied heparin–protein interactions.
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Schematic representation of the enzymatic synthesis of polysaccharides structurally related
with HP on sensor chip surfaces. Three sensor chips containing immobilized
polysaccharides were prepared.
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Diagram of the response obtained in the sensorgrams of the binding of ATIII (500 nM) with
modified heparosan after 3 min injection. Enzymatic modifications: A (N-sulfoheparosan
modified with C5-epi), AB (N-sulfoheparosan modified with C5-epi and 2-OST), ABC (N-
sulfoheparosan modified with C5-epi, 2-OST, and 6-OST), ABCD (N-sulfoheparosan
modified with C5-epi, 2-OST, 6-OST and 3-OST), ABD (N-sulfoheparosan modified with
C5-epi, 2-OST, and 3-OST), AC (N-sulfoheparosan modified with C5-epi, and 6-OST). For
a better comparison a relative response (RU of the binding/RU of the polysaccharide
immobilization) has been used.
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(A) Sensorgrams of the interaction of ATIII (100, 75, 50, 25, and 10 nM) with N-
sulfoheparosan modified with C5-epi, 2-OST, 6-OST, and 3-OST. The theoretical curves
obtained after the global fitting are in red. (B) Sensorgrams of the interaction of ATIII (10
nM) with HP (1) and N-sulfoheparosan modified with C5-epi, 2-OST, 6-OST and 3-OST
(2). The sensorgram of the interaction between ATIII and N-sulfoheparosan modified with
C5-epi, 2-OST, 6-OST, and 3-OST has been expanded. (For interpretation of the references
to color in this figure legend, the reader is referred to the web version of this paper.)
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